Replimune Group announced FDA accelerated approval of TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed on PD-1 antibody treatment. The commercial stage biotechnology company expects to launch the product within 60 days. The company recently completed a $150 million financing to support the commercial launch and ongoing IGNYTE-3 confirmatory trial. Replimune appointed Michelle DiNapoli as chief commercial officer, effective 18 August 2026. DiNapoli brings over 25 years of biopharmaceutical experience, including seven years at Deciphera Pharmaceuticals where she built the US sales force and led commercial operations. The approval represents a milestone for the company as it transitions to a fully integrated biotechnology firm.

Replimune Group (NASDAQ:REPL) CAO sells 7,632 shares. August 12, 2026 Key points. * Replimune CAO Andrew Schwendenman sold 7,632 shares at an average price of $12.97, generating about $98,987. The filing said the sale was made to cover tax-withholding obligations after equity awards vested, and he retained 99,425 shares. * Replimune shares recently traded at $15.24, near the company's 52-week high of $15.68, with a market capitalization of approximately $1.28 billion. However, the company reported a quarterly loss of $0.76 per share, missing analyst estimates of a $0.66 loss. * The company priced a $150 million public offering to fund development of its oncology pipeline and RP1, while analysts have generally turned more positive on the stock. Replimune also faces securities-class-action allegations concerning disclosures about RP1, adding legal and reputational uncertainty. * Five stocks we like better than Replimune Group. Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) CAO Andrew Schwendenman sold 7,632 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $98,987.04. Following the transaction, the chief accounting officer owned 99,425 shares of the company's stock, valued at $1,289,542.25. This represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Replimune Group stock performance. NASDAQ:REPL traded up $1.59 during mid-day trading on Wednesday, hitting $15.24. The company's stock had a trading volume of 8,269,132 shares, compared to its average volume of 5,046,735. The business's fifty day moving average is $10.34 and its two-hundred day moving average is $7.64. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -4.51 and a beta of 0.88. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. Replimune Group, Inc. has a 1 year low of $1.50 and a 1 year high of $15.68. Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.10). Analysts anticipate that Replimune Group, Inc. will post -2.45 EPS for the current fiscal year. More Replimune Group news. Here are the key news stories impacting Replimune Group this week: * Positive Sentiment: $150 million offering priced: Replimune priced a $150 million underwritten public offering, providing additional cash to support development of its oncology pipeline and RP1. The financing appears to have reassured investors about the company's liquidity and ability to fund operations. Replimune Announces Pricing of $150 Million Underwritten Offering * Neutral Sentiment: Insider transactions were primarily tax-related: CEO Sushil Patel, CFO Emily Hill, CAO Andrew Schwendenman and insider Konstantinos Xynos sold shares totaling approximately $1.01 million. The filings state that the sales covered tax-withholding obligations tied to vested equity awards, while each executive retained a substantial position; therefore, the transactions provide limited evidence of a change in business confidence. SEC insider transaction filing * Negative Sentiment: Several law firms publicized a securities class action: The lawsuits cover investors who purchased Replimune securities between October 20, 2025, and April 10, 2026. The allegations claim the company misled investors about the efficacy and commercial viability of RP1 and failed to disclose unresolved FDA study-design concerns. CEO Sushil Patel and CFO Emily Hill are named as individual defendants, and the lead-plaintiff deadline is October 5, 2026. The notices increase legal and reputational uncertainty, although the allegations have not been proven. REPL Class Action Reminder Levi and Korsinsky class action notice Analyst upgrades and downgrades. Several equities research analysts have commented on the company. JPMorgan Chase & Co. upped their price objective on Replimune Group from $17.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Weiss Ratings cut shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday. Leerink Partners raised shares of Replimune Group from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $11.00 to $17.00 in a report on Tuesday, August 4th. BMO Capital Markets upgraded shares of Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 price target on the stock in a research report on Tuesday, June 30th. Finally, Piper Sandler raised shares of Replimune Group from a "hold" rating to a "strong-buy" rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.86. Discover more EV market analysis Market cap calculator Institutional trading of Replimune Group. A number of institutional investors and hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Replimune Group by 17.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company's stock valued at $435,000 after buying an additional 6,653 shares in the last quarter. Millennium Management LLC increased its holdings in Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company's stock worth $11,927,000 after acquiring an additional 33,574 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock worth $6,729,000 after acquiring an additional 119,145 shares during the period. Rhumbline Advisers raised its position in Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company's stock worth $948,000 after acquiring an additional 6,616 shares during the period. Finally, Sei Investments Co. lifted its holdings in Replimune Group by 149.5% during the second quarter. Sei Investments Co. now owns 30,478 shares of the company's stock valued at $283,000 after purchasing an additional 18,263 shares in the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors. Replimune Group company profile. Replimune Group, Inc is a clinical-stage biotechnology company focused on developing next-generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary "RP" platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses. Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Replimune Group, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list. While Replimune Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.